Previous 10 | Next 10 |
Fortress Biotech reports positive data from CUTX-101 Fortress Biotech Inc. ( FBIO ) reported positive topline clinical efficacy data for CUTX-101. The trial is being conducted by its partner company Cyprium Therapeutics. The data showed the drug candidate brought about statistically sign...
Data from Enanta Pharmaceuticals' (NASDAQ: ENTA ) development programs for non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV) will be virtually presented at the European Association for the Study of the Liver Annual Meeting. More news on: Enanta Pharmaceuticals, Inc....
New Pharmacokinetic and Safety Results from Phase 1a Study of HBV Core Inhibitor EDP-514, Highlighting Good Safety and Tolerability, and Pharmacokinetics Suitable for Once Daily Dosing Phase 2a ARGON-1 Study for FXR Agonist EDP-305 Targeting NASH, Showing Significant Alanine Transa...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that clinical data from Enanta’s wholly-owned development programs for non-alcoholic steatohepatitis (N...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
The following slide deck was published by Enanta Pharmaceuticals, Inc. in conjunction with their 2020 Q3 earnings Read more ...
Image source: The Motley Fool. Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Q3 2020 Earnings Call Aug 4, 2020 , 4:30 p.m. ET Operator Continue reading
Enanta Pharmaceuticals, Inc. (ENTA) Q3 2020 Earnings Conference Call August 04, 2020, 16:30 ET Company Participants Jennifer Viera - Senior Director, IR & Corporate Communications Jay Luly - President, CEO & Director Paul Mellett - SVP, Finance & Administration and CF...
Enanta Pharma (NASDAQ: ENTA ) : Q3 GAAP EPS of -$0.71 beats by $0.26 . More news on: Enanta Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Initiated Phase 1b Study of EDP-514 in Viremic HBV Patients and Resumed Phase 1b Study of EDP-514 in NUC-Suppressed HBV Patients; Preliminary Data Expected in 1H 2021 and 2Q 2021, Respectively Plans to Initiate Two Phase 2 Studies of EDP-938 in Pediatric and Adult Transplant Patient...
News, Short Squeeze, Breakout and More Instantly...
Enanta Pharmaceuticals Inc. Company Name:
ENTA Stock Symbol:
NASDAQ Market:
Enanta Pharmaceuticals Inc. Website:
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strate...
2024-05-10 16:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Nuwellis Inc. (NUWE) rose 60.3% to $0.2741 on volume of 66,284,094 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 21.1% to $0.05 on volume of 64,247,106 shares Clearmind Medicine Inc. (CMND) rose 37.6% to $1.61 on volume ...